1 Safety of Cell Therapies Derived from Human Embryonic Stem Cells CTGTAC #45 April 10, 2008.

Slides:

Advertisements

Similar presentations

Introduction to Stem Cells

Advertisements

Stem Cell Dream: From Reality to Dreams. EuroStemCell is a unique partnership of European scientists, clinicians, ethicists, social scientists and science.

Stem Cells: Roadmap to the clinic Negar Azarpira, MD Associate professor of Pathology 14 April 2010.

Mitochondrial Manipulation Technologies: Preclinical Considerations

FDA Oversight of Cell Therapy Clinical Trials

Special Topics in IND Regulation

Faeze. Introduction  Stem cell therapy is certainly a promising area for research. These have the ability to give rise to many specialize cells in on.

Cellular Therapies for Cardiac Diseases – FDA Preclinical Perspective Richard D. McFarland Ph.D., M.D. CBER/OCTGT/DCEPT BRMAC # 37 March 18-19, 2004.

Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.

Principles of New Animal Drug Effectiveness: An Overview

1 FDA Regulation of Cellular, Tissue, and Gene Therapies Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies, FDA Phacilitate.

Cellular Tissue and Gene Therapies Research Site Visit Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies September 29,

Engineered Cells and Tissues Locksley McGann, PhD Professor Department of Laboratory Medicine and Pathology University of Alberta 24 April, 2012 Analytics,

Food and Drug Administration Preclinical safety data for “first in human” (FIH) clinical trials in healthy volunteer subjects Oncology Drug Advisory Committee.

Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.

Processing and Product Quality Issues Keith Wonnacott Ph.D. Office of Cellular, Tissue, and Gene Therapies E BC R Moving from Investigational to Licensed.

Howard Fillit, MD Executive Director Improving Animal Trials for Alzheimer’s Disease: Recommendations for Best Practices.

Cellular Therapy Products

Stem Cells General Concepts By Syed Tahir Abbas Shah.

Stem cells are relatively ‘unspecialized’ cells that have the unique potential to develop into ‘specialized’ cell types in the body (for example, blood.

Overview of the Clinical Trial & Protocol Jane Fendl March 31, 2010

Cellular Products for Cardiac Diseases Dwaine Rieves, MD Center for Biologics Evaluation and Research FDA Perspective on:

Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.

Biotechnology Research Project by Anna Dong, Soojin Jeong, Reina Ooka -Stem Cells-

Dermatopharmacokinetics Perspectives from Bioequivalence Viewpoint Historical Development of Dermatopharmacokinetics and Overview of the Guidance Vinod.

1 Data from Studies in One Indication Supporting Studies in a Different Indication March 5, 2003 Anti Infective Drugs Advisory Committee Meeting Edward.

1 FDA Regulation of Cell Therapy Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies Fourth Annual Translational Stem.

OCTGT Overview Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies CTGTAC Meeting July 26, 2007.

Stem Cells Mark Ellinger, Ph.D., J.D. Bethlehem Presents Series July 17,2008 Mark Ellinger, Ph.D., J.D. Bethlehem Presents Series July 17,2008.

Animal Models for Porcine Xenotransplantation Products Intended to Treat Type 1 Diabetes or Acute Liver Failure CTGTAC #47 May 14, 2009.

Exploratory IND Studies

Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

Human Embryonic Stem Cells: Considerations for Therapeutic Development Jane Lebkowski Ph.D. Geron Corporation Cell, Tissue and Gene Therapy Advisory Committee.

E BC R Overview of FDA Regulatory Issues Darin J. Weber, Ph.D. Office of Cellular, Tissue and Gene Therapies.

04/10/2008©Novocell 2008 Developing a Safe hESC-Product for Diabetes FDA Advisory Committee Meeting April 10, 2008 Melissa Carpenter, Ph.D.

CPTR Overview CPTR 2012 Workshop October 2-4, 2012.

Major Components of FDA’s Action Plan for Acrylamide Richard Canady, PhD DABT US Food and Drug Administration Center for Food Safety and Applied Nutrition.

Advances in Stem Cell Therapy Karim Nayernia Professor of Human Genetics & Stem Cell Biology.

Discovery: Stem Cell Biology Proposed Actions Continue infrastructure award program Characterize cell lines Stimulate more research on basic biology Train.

Center for Biologics Evaluation and Research, FDA Kathryn M. Carbone, M.D. Associate Director for Research.

The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.

UNDERSTANDING STEM CELLS By- Sayee Jadhav. Presentation Overview 2 1.What are stem cells? 2.What makes a cell a stem cell? 3.Types of stem cells 4.Stem.

Stage 1 Biology Semester Biotechnology

Chief, Gene Therapy Branch

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

Comments of International Society for Cellular Therapy (ISCT) to FDA Cellular, Tissue, & Gene Therapies Advisory Committee Elizabeth Read, MD March 30,

Lawrence X. Yu, Ph.D. Director for Science Office of Generic Drugs, OPS, CDER, FDA ACPS Meeting, ACPS Meeting, Oct. 22, 2003 Office of Generic Drugs Research.

21 CFR Toby A. Silverman, M.D. Branch Chief, Clinical Review Branch Division of Hematology, Office of Blood December 14, 2006.

OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation February 26, 2014.

Creating Connections. Saving Lives. ™ NATIONAL MARROW DONOR PROGRAM ® Regulation of PBSC and DLI from Unrelated Donors: Meeting the Needs of the U.S. Public.

OVERVIEWOF STEM CELLS Lecture 45 By Dr. Khaled Khalil.

STEM CELLS A cell that has the ability to continuously divide and differentiate (develop) into various other kind(s) of cells/tissues. Stem Cell Characteristics:

A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,

STEM CELLS USE OF STEM CELLS; MORTAL, ETHICAL OR MORAL?

IN THE NAME OF GOD. What are Stem Cells? Stem cells are a class of undifferentiated cells that are able to differentiate into specialized cell types.

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on the Somatic Cell.

Georgetown UNIVERSITY Overview of Gene Transfer as an Evolving Neurotherapeutic Modality Howard J Federoff, MD, PhD Georgetown University Medical Center.

We have been hearing about this stem cell lately but does everyone know about what this really is? According to medical researchers, stem cell treatments.

Pharmacology Science that studies interactions of drugs with organism on different levels (subcellular, cellular, organ, systemic) Studies: - relationship.

Stem Cells: Scientific Potential and Alternatives

Guidance for review of studies involving HCT/Ps and IND Basics

Regulatory– Terms & Definitions רגולציה - מונחים והגדרות

Stem Cells The process of cell differentiation A primary goal of research on embryonic stem cells is to learn how undifferentiated stem cells turn into.

Patient Involvement in the Development and Safe Use of

Ethical Considerations for Pediatric Clinical Investigations

Dose setting for a Phase I Clinical Study

Presentation transcript:

1 Safety of Cell Therapies Derived from Human Embryonic Stem Cells CTGTAC #45 April 10, 2008

2 Public Scientific Discussions Advisory Committee Meetings Advisory Committee Meetings Human Stem Cells as Cellular Replacement Therapies for Neurological Disorders. July 13-14, Human Stem Cells as Cellular Replacement Therapies for Neurological Disorders. July 13-14, Unrelated allogeneic hematopoietic stem/progenitor cells from placental/umbilical cord blood for hematopoietic reconstitution February 27, Unrelated allogeneic hematopoietic stem/progenitor cells from placental/umbilical cord blood for hematopoietic reconstitution February 27, Allogeneic Pancreatic Islets for Type 1 Diabetes October 9-10, 2003 Allogeneic Pancreatic Islets for Type 1 Diabetes October 9-10, 2003 Cellular Products for the Treatment of Cardiac Disease March , 2004 Cellular Products for the Treatment of Cardiac Disease March , 2004 Cellular Products for Joint Surface Repair March 3-4, 2005 Cellular Products for Joint Surface Repair March 3-4, 2005 Draft Guidance for Industry for minimally manipulated, unrelated allogeneic cord blood, and the regulatory approach to minimally manipulated unrelated allogeneic peripheral blood stem/progenitor cells. March 30, 2007 Draft Guidance for Industry for minimally manipulated, unrelated allogeneic cord blood, and the regulatory approach to minimally manipulated unrelated allogeneic peripheral blood stem/progenitor cells. March 30, 2007 Workshops Workshops FDA/NIST Sponsored Workshop In Vitro Analyses of Cell/Scaffold Products December 6-7, 2007 FDA/NIST Sponsored Workshop In Vitro Analyses of Cell/Scaffold Products December 6-7, 2007

Stem Cell-based Products: Scientific Considerations and Safety Evaluation Properties of embryonic stem cells Properties of embryonic stem cells Self renewal Self renewal Pluripotency Pluripotency Differentiation in culture Differentiation in culture Safety Evaluation Safety Evaluation Inappropriate differentiation Inappropriate differentiation Tumorigenicity Tumorigenicity Ectopic tissue formation Ectopic tissue formation StemCellStemCell ImmatureCellsImmatureCells MatureCellsMatureCells tumorigenicity 2

4 Safety Assessment 21 CFR, part (a)(8): Pharmacologic & Toxicologic Studies “…adequate information about the pharmacological & toxicological studies…on the basis of which the sponsor has concluded that it is reasonably safe to conduct the proposed clinical investigations. The kind, duration, & scope of animal and other tests required varies with the duration & nature of the proposed clinical investigations.”

5 Focus Safety issues regarding the use of cellular products derived from human embryonic stem cells Safety issues regarding the use of cellular products derived from human embryonic stem cells Discussion from CTGTAC and additional expert panelists Discussion from CTGTAC and additional expert panelists

6 Discussion Issues.. Inappropriate Differentiation/Tumorigenicity Preclinical safety assessment Preclinical safety assessment Animal species/model selection criteria Animal species/model selection criteria Clinically relevant study designs Clinically relevant study designs Site of cell implantation Site of cell implantation Fate of cells after administration Fate of cells after administration Cell dose extrapolation from animal to human Cell dose extrapolation from animal to human Study duration Study duration

7 Discussion Issues.. Product Characterization Characteristics related to safety Characteristics related to safety Ability to predict inappropriate differentiation/tumorigenicity Ability to predict inappropriate differentiation/tumorigenicity Sensitivity/specificity of assays to distinguish degree(s) of cell differentiation Sensitivity/specificity of assays to distinguish degree(s) of cell differentiation

8 Discussion Issues.. Clinical Trial Design What tools exist for monitoring the fate of infused cells during clinical trials? What tools exist for monitoring the fate of infused cells during clinical trials? Where do the cells go in the body? Where do the cells go in the body? Can we monitor inappropriate cellular differentiation in the body? Can we monitor inappropriate cellular differentiation in the body? Cell dose levels: Cell dose levels: Balancing possibility of therapeutic effect with need to ensure maximum safety Balancing possibility of therapeutic effect with need to ensure maximum safety

9 Overview Guest Presentations Guest Presentations Dr. Carpenter, Novocell Dr. Carpenter, Novocell Dr. Dinsmore, ACT Dr. Dinsmore, ACT Dr. Lebkowski, Geron Dr. Lebkowski, Geron Dr. Isacson, Harvard Dr. Isacson, Harvard Dr. Bulte, Johns Hopkins Dr. Bulte, Johns Hopkins Open Public Hearing Open Public Hearing Panel Discussion of FDA Questions Panel Discussion of FDA Questions

10 Thanks to all participants! CTGTAC #45